CSB Bancorp, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
CSBBStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| (Dollars in thousands) | 2025 | 2024 |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | $13,302 | $8,934 |
| INVESTING ACTIVITIES | ||
| Securities: | ||
| Proceeds from repayments, available-for-sale | 33,031 | 17,497 |
| Proceeds from repayments, held-to-maturity | 14,191 | 14,529 |
| Purchases, available-for-sale | (20,183) | (5,889) |
| Redemption of FHLB stock | — | 15 |
| Loan originations, net | (72,754) | (22,279) |
| Property, equipment, and software acquisitions | (349) | (1,728) |
| Purchase of bank-owned life insurance | (2,000) | (2,000) |
| Net cash (used in) provided by investing activities | (48,064) | 145 |
| FINANCING ACTIVITIES | ||
| Net increase in deposits | 51,709 | 43,104 |
| Net change in short-term borrowings | (5,379) | (16,619) |
| Repayment of other borrowings | (325) | (458) |
| Cash dividends paid | (3,219) | (3,143) |
| Purchase of treasury shares | (726) | (397) |
| Net cash provided by financing activities | 42,060 | 22,487 |
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 7,298 | 31,566 |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 73,509 | 64,077 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | $80,807 | $95,643 |
| SUPPLEMENTAL DISCLOSURES | ||
| Cash paid during the year for: | ||
| Interest | $10,998 | $10,865 |
| Income taxes | 2,500 | 2,775 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.